ArriVent Biopharma, Inc. — Form D
ArriVent Biopharma, Inc. of NEWTOWN SQUARE, PA, a company, filed a Form D exempt-offering notice with the SEC on 2021-06-23. The offering totals $90.0M, of which $81.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-06-23
- Form: D
- Accession: 0001868279-21-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $90.0M
- Amount sold: $81.0M
- Remaining: $9.0M
- Investors: 9
- Date of first sale: 2021-06-09
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-403969
Issuer
- Name: ArriVent Biopharma, Inc.
- CIK: 0001868279
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 18 CAMPUS BLVD., NEWTOWN SQUARE, PA, 19073-3269
- Phone: 240-780-6356
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| CARL GORDON | Director | SAN DIEGO, CA |
| Jason Zhang | Director | Nashville, TN |
| James Healy | Director | Sunnyvale, CA |
| Bahija Jallal | Director | Seattle, WA |
| Stuart Lutzker | Director | Newtown Square, PA |
| Zhengbin (Bing) Yao | Director | Newtown Square, PA |
| Zhengbin (Bing) Yao | Executive Officer | Newtown Square, PA |
| Cong Xu | Director | Newtown Square, PA |
Other filings by this issuer (2)
More